[go: up one dir, main page]

WO2007030571A3 - Identification of targets and development of reagents for testing and molecular imaging of human disease - Google Patents

Identification of targets and development of reagents for testing and molecular imaging of human disease Download PDF

Info

Publication number
WO2007030571A3
WO2007030571A3 PCT/US2006/034777 US2006034777W WO2007030571A3 WO 2007030571 A3 WO2007030571 A3 WO 2007030571A3 US 2006034777 W US2006034777 W US 2006034777W WO 2007030571 A3 WO2007030571 A3 WO 2007030571A3
Authority
WO
WIPO (PCT)
Prior art keywords
reagents
identification
development
targets
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034777
Other languages
French (fr)
Other versions
WO2007030571A2 (en
Inventor
Jay M D Wohlgemuth
Kirk Fry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Image Inc
Original Assignee
Molecular Image Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Image Inc filed Critical Molecular Image Inc
Publication of WO2007030571A2 publication Critical patent/WO2007030571A2/en
Publication of WO2007030571A3 publication Critical patent/WO2007030571A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention describes both the identification of disease target molecules and the development of imaging reagents and diagnostic assays specific to those molecules. Described herein are methods and reagents for the identification of molecular targets specific to a disease or disease state, methods of imaging technology which can be used, the development of specific molecular imaging reagents, clinical validation of the imaging reagents, and clinical indications for molecular imaging.
PCT/US2006/034777 2005-09-06 2006-09-06 Identification of targets and development of reagents for testing and molecular imaging of human disease Ceased WO2007030571A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71479005P 2005-09-06 2005-09-06
US60/714,790 2005-09-06

Publications (2)

Publication Number Publication Date
WO2007030571A2 WO2007030571A2 (en) 2007-03-15
WO2007030571A3 true WO2007030571A3 (en) 2007-08-30

Family

ID=37836417

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/034777 Ceased WO2007030571A2 (en) 2005-09-06 2006-09-06 Identification of targets and development of reagents for testing and molecular imaging of human disease
PCT/US2006/034703 Ceased WO2007030531A2 (en) 2005-09-06 2006-09-06 Reagents for testing and molecular imaging of liver cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034703 Ceased WO2007030531A2 (en) 2005-09-06 2006-09-06 Reagents for testing and molecular imaging of liver cancer

Country Status (1)

Country Link
WO (2) WO2007030571A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014404A2 (en) 2006-07-26 2008-01-31 The University Of Chicago Receptor-mediated delivery : compositions and methods
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
CN102014937A (en) 2008-03-03 2011-04-13 迈阿密大学 Allogeneic cancer cell-based immunotherapy
DE102008039417A1 (en) * 2008-08-13 2010-02-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Agent for the detection and treatment of prostate cells
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US20120190049A1 (en) * 2010-12-10 2012-07-26 University Of Washington Through Its Center For Commercialization Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
US8900822B2 (en) 2011-11-21 2014-12-02 Ethicon, Inc. Fibrinogen assay
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
SMT202100180T1 (en) 2013-10-11 2021-05-07 Oxford Bio Therapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CN107328746B (en) * 2017-06-14 2020-01-31 宁波大学 Preparation and application of multifunctional fluorescent biosensors based on nucleic acid-like coordination polymers
CN111273010B (en) * 2018-12-04 2023-04-18 北京蛋白质组研究中心 Application of kit for detecting SOAT1 protein expression level in preparation of hepatocellular carcinoma screening product
US20200191785A1 (en) * 2018-12-18 2020-06-18 Euroimmun Medizinische Labordiagnostika Ag Method for Diagnosing Autoimmune Gastritis
CN109701039A (en) * 2019-01-17 2019-05-03 浙江大学 A kind of preparation method of liver cancer dual-target magnetic nanoparticle
CN109897900B (en) * 2019-03-13 2023-04-07 温州医科大学 Application of EPB42 gene in liver cancer SBRT curative effect evaluation
JP7353396B2 (en) * 2019-06-14 2023-09-29 シージーン アイエヌシー Computer processing method for collaborative development of target nucleic acid detection reagents
CN115166245A (en) * 2021-04-04 2022-10-11 兰州大学第一医院 Application of CLU and its composition in the diagnosis of cholangiocarcinoma and diagnostic kit for cholangiocarcinoma
CN113249476B (en) * 2021-05-12 2022-10-14 复旦大学 Key protein BLT2 influencing tumor cell dryness and application thereof
CN113151482A (en) * 2021-05-21 2021-07-23 深圳泰莱生物科技有限公司 Method for identifying benign and malignant lung nodules based on monochromatic multiple fluorescence quantitative PCR
CN117647645B (en) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Application of LBP, ATF6 and M-CSFR combination in preparation of product for diagnosing autoimmune liver disease and kit
CN118471472B (en) * 2024-05-22 2025-07-22 中国人民解放军海军军医大学第三附属医院 Marker, kit, system and application for screening or diagnosing early liver cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US20020081640A1 (en) * 2000-06-28 2002-06-27 Macina Roberto A. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20050130167A1 (en) * 2002-10-25 2005-06-16 Gang Bao Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20050192458A1 (en) * 2002-04-30 2005-09-01 Goodman Mark M. Tumor imaging compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168711A1 (en) * 2000-01-31 2002-11-14 Rosen Craig A. Nucleic acids, proteins, and antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US20020081640A1 (en) * 2000-06-28 2002-06-27 Macina Roberto A. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20050192458A1 (en) * 2002-04-30 2005-09-01 Goodman Mark M. Tumor imaging compounds
US20050130167A1 (en) * 2002-10-25 2005-06-16 Gang Bao Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring

Also Published As

Publication number Publication date
WO2007030571A2 (en) 2007-03-15
WO2007030531A2 (en) 2007-03-15
WO2007030531A3 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2005114190A3 (en) Methods of identifying biomarkers
WO2006079049A3 (en) Methods and compositions for increased dynamic range detection of nucleic acid molecules
WO2007137187A3 (en) System and method for determining individualized medical intervention for a disease state
WO2008021290A9 (en) Organ-specific proteins and methods of their use
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2007117444A3 (en) Protein detection by aptamers
EP2021512A4 (en) Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
WO2007019492A3 (en) Methods for detection of a nucleic acid by sequential amplification
WO2010027903A3 (en) Lung cancer diagnosis
WO2007133682A3 (en) 100% sequence identity detection methods for variable genomes
WO2008008708A3 (en) Lung cancer diagnostic assay
WO2004092734A3 (en) Novel approach to molecular diagnosis of human papilloma virus-related diseases
EP2535718A3 (en) Methods for early diagnosis of kidney disease
WO2007079284A3 (en) Lung cancer diagnostic assay
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
WO2007132120A3 (en) Procedure and methods for detecting alzheimer's disease
WO2008012650A3 (en) An immunochromatography device for the diagnosis of diseases in a sample
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
WO2002092858A3 (en) Methods of screening for disease
WO2008089155A3 (en) Biomarker assays for the diagnosis of malaria in developing countries based on epo levels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06814248

Country of ref document: EP

Kind code of ref document: A2